Q3 EPS Estimates for Cytosorbents Reduced by Zacks Research

Cytosorbents Corporation (NASDAQ:CTSO) – Stock analysts at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for Cytosorbents in a note issued to investors on Monday, August 17th. Zacks Research analyst T. Kerr now forecasts that the medical research company will post earnings per share of ($0.05) for the quarter, down from their previous forecast of ($0.04). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.21) per share. Zacks Research also issued estimates for Cytosorbents’ FY2026 earnings at ($0.22) EPS and FY2027 earnings at ($0.09) EPS.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The company had revenue of $9.63 million during the quarter, compared to the consensus estimate of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cytosorbents presently has a consensus rating of “Hold” and an average target price of $5.38.

Cytosorbents Stock Down 1.1%

CTSO stock opened at $0.36 on Thursday. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. Cytosorbents has a fifty-two week low of $0.35 and a fifty-two week high of $1.04. The firm’s 50-day simple moving average is $0.39 and its 200 day simple moving average is $0.53. The stock has a market cap of $22.37 million, a PE ratio of -1.23 and a beta of 1.39.

Insider Buying and Selling at Cytosorbents

In other news, CEO Phillip P. Chan bought 251,136 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $0.40 per share, with a total value of $100,454.40. Following the completion of the acquisition, the chief executive officer directly owned 1,734,099 shares in the company, valued at approximately $693,639.60. This trade represents a 16.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CTSO. Goldman Sachs Group Inc. grew its holdings in Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the period. Vanguard Group Inc. lifted its holdings in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Cytosorbents during the 3rd quarter valued at about $161,000. Finally, CM Management LLC raised its holdings in shares of Cytosorbents by 14.6% in the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after purchasing an additional 188,372 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.